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Abstract
Objective—Smooth muscle cell (SMC) differentiation is a dynamic process that must be tightly
regulated for proper vascular development and to control the onset of vascular disease. Our lab
previously reported that a specific focal adhesion kinase (FAK) inhibitor termed FRNK (FAK
Related Non-Kinase) is selectively expressed in large arterioles when SMC are transitioning from a
synthetic to contractile phenotype and that FRNK inhibits FAK-dependent SMC proliferation and
migration. Herein, we sought to determine whether FRNK expression modulates SMC phenotypes
in vivo.
Methods and Results—We present evidence that FRNK−/− mice exhibit attenuated SM marker
gene expression during post-natal vessel growth and following vascular injury. We also show that
FRNK expression is regulated by TGF-β and that forced expression of FRNK in cultured cells induces
serum- and TGF-β-stimulated SM marker gene expression, while FRNK deletion or expression of a
constitutively activated FAK variant attenuated SM gene transcription.
Conclusions—These data highlight the possibility that extrinsic signals regulate the SMC gene
profile, at least in part, by modulating the expression of FRNK and that tight regulation of FAK
activity by FRNK is important for proper SMC differentiation during development and following
vascular injury.
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While medial smooth muscle cells (SMC) found in the mature vessel are fully differentiated
and express high levels of SM contractile proteins, these cells do not terminally differentiate
and can transition to a synthetic phenotype characterized by low levels of SM contractile gene
expression and responsiveness to pro-growth and migratory signals. This unique plasticity is
critical for proper vessel development, blood pressure homeostasis, and injury repair processes.
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A number of secreted growth factors (i.e. platelet derived growth factor (PDGF-BB),
sphingosine 1-phosphate (S1P), transforming growth factor-β (TGF-β) and contractile agonists
(angiotensin II, endothelin-1 and thrombin) have been shown to regulate SMC phenotype in
vitro and in vivo.3 In addition to levels of circulating factors, studies have also shown that the
extracellular matrix (ECM) that surrounds SMC in the vessel wall can impart control over SM
phenotypes.4 Indeed, genetic ablation of either fibronectin or the α5 integrin fibronectin
receptor results in embryonic lethality associated with impaired SMC investment of both
embryonic and extraembryonic vessels.5, 6 Although the precise signaling mechanisms by
which these diverse agonists and ECM regulate SMC transcription have not been completely
delineated, several studies indicate that many (but not all) SM-specific genes (particularly
contractile genes) depend on the presence of an serum response factor (SRF) DNA binding
element termed a CArG box (CC(A/T)6GG) and many of these aforementioned intrinsic factors
alter SRF or SRF-cofactor activity.3, 7–10
One of the major proteins involved in the integrin intracellular signaling cascade is the non-
receptor protein tyrosine kinase, focal adhesion kinase (FAK), which is strongly and rapidly
activated by various aforementioned growth factors and by ligation of all β1, β3 or β5 containing
integrins.11 Although a direct role for FAK in vascular growth and development has yet to be
examined, germline deletion of FAK phenocopies the lethal defects observed in
fibronectin−/− and α5 integrin−/− embryos. Interestingly, our lab recently showed that FAK
activity is regulated in a unique fashion in SMC, whereby a separate protein comprising the
carboxyterminus of FAK, termed FRNK (FAK Related Non Kinase) that acts as a dominant-
interfering mutant for FAK is selectively expressed in SMC with very high levels found in the
large arterioles. FRNK transcription results from the utilization of an alternative start site within
the FAK gene and FRNK expression is independently regulated by a distinct promoter
embedded within FAK intronic sequences.12, 13 Whereas FAK protein levels remain relatively
constant during vascular development, FRNK protein levels are dynamically increased in
neonatal vessels and in adult vessels two weeks following injury, when SMC are transitioning
from a synthetic to contractile phenotype.
The aim of this study was to determine whether FRNK expression plays a direct role in the
phenotypic modulation of SMC in vivo. Herein we present evidence that FRNK−/− mice exhibit
repressed SM marker gene expression during post-natal vessel growth and following vascular
injury. These data highlight the possibility that extrinsic signals regulate the SMC gene profile
by modulating the dynamic expression of FRNK.
METHODS
Mice were housed in an AALAC accredited University Animal Care Facility and all
experimental procedures were approved by the University of North Carolina animal care and
use committee (IACUC). All quantitative data represent at least three separate experiments
presented as mean +/− SEM. Means were compared by 2-tailed Students’s t test and p<0.05
was considered statistically significant as indicated by an asterisk. All other data including
Western analysis are representative of at least three individual experiments. Please see Online
Supplemental Data section for a complete description of the animal models, reagents, DNA
constructs, and general methods used for these studies.
RESULTS
The 41/43 kDa FRNK protein is selectively expressed in the vasculature from approximately
E12.5 onward with highest levels observed in large arterioles and lung of neonatal rats (post-
natal day 4–14) (Fig 1B).12,14 FRNK protein was also detected in cells derived from human
aorta and coronary arteries and coronary SMC cultures derived from explanted pro-epicardial
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organs, but not in cultured endothelial cells (please see www.ahajournals.org, online Fig I). As
previously reported (and depicted in Fig 1A), FRNK expression is regulated by a promoter
embedded within the fak gene and frnk transcription initiates from a non-coding exon located
approximately 300 bp upstream of the FRNK translational start site in the mouse gene. 12,
13 Since FRNK shares the same amino acid sequence as the C-terminus of FAK, we have been
unable to develop a specific antibody that recognizes FRNK (but not FAK) for
immunohistochemical analysis of FRNK expression patterns. However, since the frnk non-
coding exon is selectively protected in RNA isolated from SMC and SMC-containing tissues,
12 we developed an in situ probe directed against this unique sequence to examine FRNK
expression patterns in vivo. Our in situ analysis of tissues harvested from post-natal day 7 mice
revealed that FRNK is expressed throughout the media of large arterial vessels, but is not
expressed in either the endothelium or adventitial layer (Fig 1C, top). Some visceral SMC
staining was apparent as well, with high levels observed in the lung (Fig 1C) and bladder (not
shown). FRNK expression in the lung was localized to the smooth muscle lining of the bronchi
in addition to vessels, similar to the staining pattern observed for SMα-actin. 16 Further analysis
of FRNK expression in the developing mouse vasculature using quantitative RT-PCR revealed
a dynamic up-regulation of FRNK mRNA in aorta between 7 and 10 days post-natal,
corroborating our previous Western analysis (Fig 1D).
We reasoned that up-regulation of FRNK in the neonatal vessels may serve to buffer FAK-
dependent signals in this environment that is particularly rich in growth factors and matrices
known to be up-stream activators of FAK. Thus we sought to identify some of the mechanisms
involved in the transient and dynamic regulation of FRNK expression in post-natal vessels. To
determine the relative stability of FRNK protein, we treated SMC with cyclohexamide for
various times and analyzed FRNK and FAK levels. In support of the idea that FRNK expression
can be tightly regulated, we found that FRNK protein turnover is relatively rapid, with an
apparent half-life of approximately 4.5 hr (please see www.ahajournals.org, online Fig IIA).
The level of FAK protein was not significantly changed during the 8 hr time-course examined,
consistent with previous reports that FAK protein is extremely stable with a half-life exceeding
20 hr26. We next sought to identify factors that can modulate dynamic FRNK expression during
vascular morphogenesis. We first utilized a FRNK promoter reporter construct to define factors
that regulate FRNK transcription. A fragment comprising approximately 6kb of sequence
upstream of the FRNK ATG (−5388 to +876) was previously shown to drive SM-specific
expression of LacZ in vivo in a pattern reminiscent of FRNK expression.14 Importantly, we
found that the corresponding FRNK promoter attached to a luciferase reporter (FRNK-Luc)
exhibited high activity in cultured SMC in comparison to 10T1/2 cells (consistent with the
levels of FRNK expressed in these two cell types, please see www.ahajournals.org, online Fig
IIB). Although FRNK is expressed in a SM-restricted fashion, careful analysis of the FRNK
promoter region from chicken, mouse and human sequence did not reveal any conserved CArG
elements, known to direct SRF-dependent transcription. Indeed, co-expression of SRF and
FRNK-Luc in SRF−/− ES cells did not alter basal FRNK-Luc promoter activity in these cells,
while reconstitution of SRF induced expression of a SMα-actin-Luc construct approximately
15-fold (Fig 2A). Moreover, when expressed in SMC, the FRNK-Luc construct was un-
responsive to over-expression of the myocardin family of SRF co-factors, which stimulated
strong activation of the SMα-actin-Luc reporter (please see www.ahajournals.org, online Fig
IIC). Furthermore, ectopic expression of myocardin did not alter FRNK message levels but
induced a striking 60-fold increase in SM22 message (Fig 2B). Collectively, these data provide
strong support for FRNK being expressed in a non-SRF/CARG dependent fashion as
previously suggested.22
We next screened a number of cytokines/growth factors known to be released following vessel
injury for their ability to increase FRNK promoter and protein levels in cultured rat aortic SMC.
We found that TGF-β induced a marked increase in FRNK-Luc activity, FRNK mRNA (as
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assessed by quantitative RT-PCR) and protein levels compared to vehicle treated cells (Fig
2C–E), while other agonists including the potent SMC mitogens PDGF-BB, S1P, angiotensin
II, thrombin, and basic-fibroblast growth factor had no effect (data not shown). The ability of
SB 431542 (a selective inhibitor of the TGF-β1 activin receptor-like kinase; ALK-5) to
dramatically reduce expression of FRNK in cultured SMC under serum-starved conditions or
following TGF-β treatment strongly supports the idea that TGF-β is a major regulator of FRNK
expression (Fig 2E).
Since TGF-β induces FRNK expression and SM differentiation, we theorized that FRNK might
promote SMC phenotypic switching from a synthetic to contractile state. To directly explore
this possibility, we performed SMC promoter-reporter assays in 10T1/2 cells, a multi-potential
SMC precursor line that has been shown to markedly up-regulate SMC-specific gene
expression upon stimulation with serum, S1P, or TGF-β.19, 20 While FRNK protein is not
expressed in detectible levels in 10T1/2, FRNK message is detectible by quantitative RT-PQR
(data not shown) and forced expression of FRNK in these cells inhibited FAK activity and
resulted in a two to four-fold increase in SM22, SMα-actin and SM-MHC promoter activity,
without effecting myocardin levels (Fig 3A, please see www.ahajournals.org, online Fig
IIIA,B). We reasoned that FRNK expression likely promotes SMC differentiation by relieving
FAK-dependent repressive signals. To determine whether FAK activation limits SM marker
gene expression we ectopically expressed a constitutively active FAK variant (termed
SuperFAK21) that leads to enhanced FAK activity as assessed by phosphorylated Y397FAK
levels. As expected, SuperFAK expression in 10T1/2 cells significantly reduced SM22 (Fig
3B) and SMα-actin reporter gene expression (please see www.ahajournals.org, online Fig
IIIC). Similarly, ectopic expression of FRNK and FAK variants in primary rat aortic SMC
revealed an inverse relationship between FAK activity and SM gene expression (i.e. low FAK
activity correlates with high levels of SM markers, Fig 3C, please see www.ahajournals.org,
online Fig IIID). Taken together, our findings provide compelling evidence that FAK activity
limits SMC differentiation, and up-regulation of FRNK promotes differentiation by attenuating
FAK activity.
We next examined TGF-β stimulated SM gene expression in our cell culture models. We found
that TGF-β and FRNK acted in concert to induce SM22 reporter activity in 10T1/2 cells (Fig
3D). Importantly, similar results were observed when we analyzed endogenous SM gene
expression by Western analysis. SM22 protein was un-detectible in 10T1/2 cells under basal
conditions, but either expression of FRNK or treatment of cells with TGF-β for 48 hours
induced a modest increase in SM-22, and when combined, these agents markedly increased
SM22 expression (Fig 3E). FRNK and TGF-β each individually led to a similar marked
induction of SMα-actin protein levels in 10T1/2 cells, however, the combined treatment had a
more modest effect, most likely due to the already high levels of SMα-actin induced by each
factor alone. Collectively, these data provide support for a model whereby TGF-β induces
FRNK expression and that FRNK, in turn, contributes to TGF-β induced SMC differentiation
by dampening FAK-dependent signals.
We next strove to evaluate FRNK's function to regulate SMC phenotype in post-natal vessels.
FRNK−/− mice were recently generated by a strategy that resulted in deletion of a 1kb fragment
that included the non-coding exon and 700 bp of upstream fak intronic sequence (see schematic
in Fig 1A). Although these mice were born in the expected Mendelian frequency and showed
no gross phenotype, they were not specifically examined for defects in SMC differentiation
marker gene expression or growth. 14 Since the timing of FRNK expression during
development and following vascular injury correlates with the conversion of SMC from a
synthetic to contractile phenotype, we first examined the proliferation index of medial SMC
in post-natal vessels from wild type or FRNK−/− mice. As shown in Figure 4A, medial SMC
in postnatal FRNK−/− vessels exhibit a significantly higher index of BrdU incorporation in
Sayers et al. Page 4













comparison to littermate control vessels. Importantly, SMC tissue from postnatal FRNK−/−
pups reveal lack of FRNK protein and higher levels of active pY397FAK, in comparison to wild
type littermate controls, while total FAK protein levels are unaltered (Fig 4B).
We next analyzed the dynamic expression of the contractile genes, SMα-actin, SM-22, and
smoothelin B in the aorta of post-natal control and FRNK−/− mice by quantitative RT-PCR.
Expression of these contractile genes is enhanced approximately 6–10 fold from 4 day post-
natal to adult vessels in wild type mice (data not shown). Interestingly, we found that
FRNK−/− vessels contain significantly fewer transcripts of these genes in the 2–3 week period
of vessel development when compared to age and littermate controls, when FRNK protein is
most highly abundant in wild type vessels (Fig 4C).12 However, no significant differences in
SM marker gene expression was observed in adult aorta (see data for 8 week animals in Fig
4C) or carotid vessels isolated from wild type or FRNK−/− mice (Fig 5A), indicating that the
lag in SM differentiation observed in the neonatal vessels was normalized during vessel
maturation. In spite of these transient significant differences in SMC phenotype, we did not
detect any significant difference in medial thickness of FRNK−/− adult arterioles (aorta or
carotids) in comparison to littermate control vessels analyzed from 7 days post-natal to adult
(please see www.ahajournals.org, online Fig IV). Also, we found that adult FRNK−/− mice did
not exhibit significant changes in mean systolic blood pressure (as assessed by tail cuff
measurements) or pressor responses (as assessed by intra-aortic catheterization) following
phenylephrine treatment in comparison to wild type littermate controls (please see
www.ahajournals.org, online Fig IV), indicating that FRNK expression does not function to
regulate vascular homeostasis in adult mice (see online Supplemental Data section for further
discussion).
Since we previously reported that FRNK expression is relatively low in adult vessels, but is
dramatically up-regulated by 14 days following catheter-induced vessel injury, we postulated
that FRNK might also regulate SMC phenotypic switching during restenosis. Numerous studies
have revealed that contractile gene expression is dynamically regulated following vascular
injury induced by either vessel ligation or surgical endothelial denudation. Typically, reduced
SMC marker gene expression is apparent within 3–7 days following injury followed by a burst
of re-expression after approximately 2–3 weeks.17, 18 To examine a possible involvement of
FRNK in the regulation of SMC re-differentiation following vascular injury, we performed
quantitative RT-PCR for SM marker genes in wild type and FRNK−/− carotid arteries 7–21
days following carotid ligation. As shown in figure 5, significant decreases in re-expression of
SMα-actin, SM-22, and smoothelin B (but not β-actin) were observed in FRNK−/− vessels in
comparison to littermate controls, indicating that the recovery of SM differentiation was
defective in injured FRNK−/− arteries. Notably, no significant differences in SM gene
expression were observed in the control un-ligated right carotid artery at the time points
examined (data not shown). Concomitantly, immunohistochemical analysis for SMα-actin
revealed a striking difference between wild type and FRNK−/− vessels 14 days after ligation.
While, robust SMα-actin staining was observed throughout the media and neo-intima of wild
type vessels, SMα-actin expression in the neoinitma of FRNK−/− vessels was markedly reduced
(Fig 5D). While we anticipated that this phenotype might lead to a more exacerbated injury
response, morphometric analysis at this time point revealed no significant differences in the
extent of remodeling induced by ligation of wild type and FRNK−/− vessels, likely due to the
fact that the ligation induces a very strong proliferative response in the wild type mice (please
see www.ahajournals.org, online Fig V). Indeed, by 21 days after ligation full occlusion of
injured vessels was observed in both wild type and FRNK−/− mice. Collectively, these data
provide strong support for the hypothesis that up-regulation of FRNK expression following
vessel injury is required for appropriate SMC maturation that occurs subsequent to injury
repair.
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Finally, we utilized cultures derived from FRNK−/− mice to confirm our previous in vitro and
in vivo findings. We found that aortic SMC isolates from FRNK−/− mice consistently exhibited
enhanced pY397FAK, and lower levels of the contractile proteins SM22, SMα-actin, and SM-
MHC than SMC isolates from aged matched (and passage-matched) control mice (Fig 6A),
while these cells maintained similar morphology (please see www.ahajournals.org, online Fig
VI). The low levels of SMC proteins in FRNK−/− SMC may reflect the inability of these cells
to maintain a differentiated phenotype in these pro-growth culture conditions (see online
Supplemental Data section for further discussion). In support of the notion that FRNK acts to
enhance TGF-β dependent gene expression, we found that TGF-β-induced expression of
endogenous SM22 was significantly decreased in FRNK−/− SMC in comparison to matched
wild type SMC isolates (Fig 6B). We also noticed that the FRNK−/− cells exhibited high growth
rates and were more motile than control SMC isolates (data not shown). To directly test that
these differences were due to lack of FRNK expression, we next re-constituted FRNK in
FRNK−/− cells. As shown in figure 6 C–E, re-expression of FRNK in these cultures
significantly increased SMα-actin expression, but significantly decreased both BrdU
incorporation and PDGF-stimulated motility.
DISCUSSION
FRNK, a dominant interfering mutant that attenuates FAK activity, exhibits selective and
dynamic expression in SMC. We previously reported that FRNK attenuates SMC proliferation
and migration by regulating FAK/Rac1-dependent signaling.23 Herein we have found an
additional function for FAK/FRNK signaling in SMC. We present evidence that FRNK
deletion (by homologous recombination) represses SM gene expression during post-natal
vessel growth and following vascular injury. We also show that FRNK expression is regulated
by TGF-β and that forced expression of FRNK induces SM marker gene expression in cultured
cells grown in serum and enhances TGF-β-stimulated SM marker gene expression. Conversely,
FRNK deletion or expression of a constitutively activated FAK variant attenuated SM gene
transcription. These data suggest that enhanced FAK activity is permissive for SMC growth
and migration, but limits SM differentiation, and that tight regulation of FAK activity is likely
important for proper SMC phenotypic modulation during development and following vascular
injury.
FAK is activated by a process that involves dimerization and intermolecular phosphorylation
of tyrosine 397 in trans.24 Phosphorylation of Y397 results in subsequent recruitment of the
tyrosine kinase Src (and/or Fyn), which phosphorylates and further activates FAK (and
phosphorylates certain FAK binding partners).11 FRNK likely attenuates FAK activity by
inducing the formation of FRNK/FAK heterodimers that are incapable of Y397
phosphorylation and Src binding. In support of this notion, expression of wild type FAK (and
Src) can rescue FRNK-dependent inhibition of FAK (and paxillin) phosphorylation, while
expression of a phospho-deficient Y397FFAK cannot.25 Our findings indicating that FAK
activity is enhanced in tissues and cells derived from FRNK−/− mice strongly supports the
hypothesis that the dynamic regulation of FRNK expression can impart specific spatial and
temporal control of FAK activity in vivo. In this regard, it is interesting to note that FAK protein
is extremely stable with a reported half-life exceeding 20 hr,26 while we found that FRNK
protein turnover is rapid. We speculate that transient FRNK expression is particularly important
in the vasculature, where direct apposition of SMC with extracellular matrix could lead to high
levels of FAK activation and un-controlled SM growth. It is feasible, however, that FRNK has
additional FAK-independent functions, and future studies will examine this possibility.
In support of the idea that FRNK/FAK signaling plays an active role in regulating smooth
muscle cell phenotypes, FAK−/− mouse embryonic fibroblasts were recently reported to exhibit
a myo-fibroblast appearance as assessed by high levels of SM α-actin containing stress fibers
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relative to control fibroblasts.27 Interestingly, we recently found that FAK-deficient SMC (like
FRNK over-expressing SMC) exhibit enhanced TGF-β stimulated SM marker gene expression
(un-published observations; see Supplemental Data section for further discussion). In addition,
recent studies have provided evidence for a role of FAK in promoting striated muscle cell
differentiation as the dynamic regulation of FAK activity was found to be essential for
differentiation of C2C12 myoblasts into myotubes.28 Also, a role for FAK in the promotion of
cardiogenesis was suggested by studies in which stable expression of FRNK in ES cells was
shown to induce cardiac α-myosin heavy chain and sarcomeric myosin expression.29 Since
SRF plays a critical role in the regulation of contractile gene expression in each of these muscle
types, it will be of future interest to determine whether limiting FAK activity regulates SRF
activity and/or co-factor recruitment.
Since FRNK exhibited a striking SMC-restricted expression pattern, we sought to explore the
mechanisms underlying its transcriptional regulation. Interestingly, we found that the FRNK
promoter does not contain a canonical CArG box, is not affected by SRF deletion, and is un-
responsive to over-expression of the myocardin family of potent SRF co-factors. Thus, FRNK
belongs to a sub-class of smooth muscle specific genes that are regulated in a CArG-
independent fashion including aortic carboxypeptidase-like protein (ACLP), cysteine-rich
protein 2 (CRP2), and histidine-rich calcium-binding protein (HRCBP) (see Supplemental
Data for further discussion)30–32 Interestingly, TGF-β, a strong activator of SMC
differentiation, led to significant up-regulation of FRNK expression. Thus, future exploration
of the TGF-β-dependent mechanisms that control FRNK expression may lead to identification
of additional transcription factors that regulate SMC phenotypes.
Although reported to affect a wide variety of cellular processes a principal function for FAK
in numerous cell types is its ability to modulate integrin and growth factor receptor-stimulated
cellular migration.11 Direct evidence for the role of FAK in modulating fibronectin-dependent
motility was previously shown using FAK−/− fibroblasts, endothelial cells, neurons, and
keratinocytes.33–36 We previously showed that FRNK expression in SMC attenuated FAK-
dependent PDGF-stimulated chemotaxis12 and our recent studies reveal that FAK−/− SMC
exhibit a similar defect (un-published observations). Since FRNK appears to play a dual role
in SM function; aiding to block SMC growth and migration and to promote SMC
differentiation, FRNK may function as a toggle in the regulation of SMC phenotypes.
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Figure 1. FRNK is expressed selectively in smooth muscle containing-tissues
A. Schematic of FAK and FRNK cDNA and genomic locus. Shaded areas represent FAK-
specific (blue), FRNK-specific (green), or common (red) coding regions. B. Western analysis
of 14d postnatal rat tissues. C. In situ hybridization for FRNK and SMα-actin in postnatal day
7 mouse aorta and lung. D. Quantitative RT-PCR for FRNK in thoracic aorta. (Mean +/− SEM
n >/= 4, * p < 0.01, # p < 0.05).
Sayers et al. Page 10













Figure 2. FRNK expression is regulated by TGF-β but is SRF/CArG independent
A. SRF−/− ES cells were co-transfected with indicated constructs and processed for luciferase
activity. B. qRT-PCR in 10T1/2 cells transfected with Flag or Flag-Myocardin. C,D. FRNK
luciferase assay in 10T1/2 cells (C) or qRT-PCR in rat aortic SMC dosed with vehicle or TGF-
β (1 ng/mL) for 24 hr in media containing 0.2% serum. E. Western analysis of rat SMC
pretreated with SB 431542 for 15 min and then dosed with TGF-β (1 ng/mL) or vehicle for 48
hours. N>/=3.
Sayers et al. Page 11













Figure 3. SM marker gene expression is induced by FRNK expression
A–D. SM-22 luciferase assay in 10T1/2 cells (A, B, D) or rat aortic SMC of cells (C) performed
in 10% serum-containing media (A–C) or media containing 0.2% serum and treated with
vehicle or TGF-β (1 ng/mL) for 24 hrs (D). Mean +/− SEM; n>/=3. E. Western analysis of
10T1/2 cells transfected with Flag or Flag-FRNK and treated with TGF-β (1 ng/mL) for 48 hrs
in media containing 0.2% serum. Densitometry of 4 separate experiments is indicated
numerically.
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Figure 4. FRNK−/− mice exhibit increased SM proliferation and attenuated expression of SM
marker genes during development
A. BrdU incorporation in post-natal day 4 thoracic aorta collected from wild type (+/+) or
FRNK−/− (−/−) mice (Mean +/− SEM (n=5, p<0.03). B. Western analysis in post-natal day 4
bladders from heterozygous (+/−) or FRNK−/− (−/−) pups. C. Quantitative RT-PCR for
indicated SM differentiation markers in +/+ and −/− thoracic aorta. Data is normalized to
expression of 18S and is expressed as the mean percent of wild type expression at each time
point +/− SEM (n > 4 for each time point, ** p < 0.01, * p < 0.05).
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Figure 5. FRNK−/− mice show decreased expression of SM marker genes following carotid artery
ligation
Wild type (+/+) or FRNK−/− (−/−) mice were subjected to left carotid blood flow. A-C. qRT-
PCR for the indicated SM markers and β-actin (control). Data is presented as the left carotid
normalized to expression in the wild type right (control) carotid artery at each timepoint +/−
SEM (n >4, * p<0.01, # p<0.05). D. Verhoeff’s elastin and immunohistochemistry for SM α-
actin in carotids from wild type (+/+) or FRNK−/− (−/−) mice 14 days following ligation. Black
bars indicate thickness of neointima. Data are representative of at least three separate animals
from each genotype.
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Figure 6. Cultured SMC isolated from FRNK−/− mice exhibit a synthetic phenotype
A. Western analysis of primary cell isolates harvested from 6 week post-natal wild type (+/+)
or FRNK−/− (−/−) mice (data are representative of three separate cell isolates per genotype).
B. qRT-PCR for SM-22 message in wild type (+/+) or FRNK−/− (−/−) cells serum starved and
treated with TGF-β for 24 hr. C–E. FRNK−/− cells infected with GFP or GFP-FRNK
adenovirus were subjected to qRT-PCR (C), BrdU incorporation (D) or chemotaxis (E) assays.
Data are presented as mean +/− SEM (n=3).
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